JAHA:围产期妇女的体外生命支持临床研究

2020-06-27 MedSci原创 MedSci原创

体外生命支持(ECLS)的使用已经扩大到包括围产期妇女等特殊人群。本系统回顾旨在量化文献报道的围产期妇女ECLS的病例数和适应证,以及报告与围产期ECLS相关的母婴并发症和结局。

体外生命支持(ECLS)的使用已经扩大到包括围产期妇女等特殊人群。本系统回顾旨在量化文献报道的围产期妇女ECLS的病例数和适应证,以及报告与围产期ECLS相关的母婴并发症和结局。

本研究纳入分析了来自221篇文献报道的358名妇女,母亲30天的总存活率为270(75.4%),1年的总存活率为266(74.3%),胎儿存活率为44(64.7%)。妊娠期ECLS最常见的指征包括急性呼吸窘迫综合征177例(49.4%),心衰67例(18.7%),心搏骤停57例(15.9%)。最常见的母亲并发症包括轻度至中度出血66例(18.4%),需要手术治疗的严重出血48例(13.4%),颅内神经系统疾病19例(5.3%)。最常见的胎儿并发症包括早产33例(48.5%)和新生儿重症监护室入院19例(27.9%)。

研究结果显示,对于接受体外生命支持的围产期妇女来说,生存率较高,主要并发症发生率较低。

原始出处:

Emily E. et al.Extracorporeal Life Support in Pregnancy: A Systematic Review.JAHA.2020 June.

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1693849, encodeId=e1371693849e3, content=<a href='/topic/show?id=3531265656b' target=_blank style='color:#2F92EE;'>#体外生命支持#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26565, encryptionId=3531265656b, topicName=体外生命支持)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=777829458008, createdName=whlxd, createdTime=Fri Apr 30 16:58:16 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078970, encodeId=a5f920e89707e, content=<a href='/topic/show?id=9911689430e' target=_blank style='color:#2F92EE;'>#生命支持#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68943, encryptionId=9911689430e, topicName=生命支持)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Mon Sep 14 00:58:16 CST 2020, time=2020-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268279, encodeId=121812682e9f6, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Mon Jun 29 12:58:16 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800154, encodeId=8196800154b2, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Sun Jun 28 20:35:12 CST 2020, time=2020-06-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1693849, encodeId=e1371693849e3, content=<a href='/topic/show?id=3531265656b' target=_blank style='color:#2F92EE;'>#体外生命支持#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26565, encryptionId=3531265656b, topicName=体外生命支持)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=777829458008, createdName=whlxd, createdTime=Fri Apr 30 16:58:16 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078970, encodeId=a5f920e89707e, content=<a href='/topic/show?id=9911689430e' target=_blank style='color:#2F92EE;'>#生命支持#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68943, encryptionId=9911689430e, topicName=生命支持)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Mon Sep 14 00:58:16 CST 2020, time=2020-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268279, encodeId=121812682e9f6, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Mon Jun 29 12:58:16 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800154, encodeId=8196800154b2, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Sun Jun 28 20:35:12 CST 2020, time=2020-06-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1693849, encodeId=e1371693849e3, content=<a href='/topic/show?id=3531265656b' target=_blank style='color:#2F92EE;'>#体外生命支持#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26565, encryptionId=3531265656b, topicName=体外生命支持)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=777829458008, createdName=whlxd, createdTime=Fri Apr 30 16:58:16 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078970, encodeId=a5f920e89707e, content=<a href='/topic/show?id=9911689430e' target=_blank style='color:#2F92EE;'>#生命支持#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68943, encryptionId=9911689430e, topicName=生命支持)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Mon Sep 14 00:58:16 CST 2020, time=2020-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268279, encodeId=121812682e9f6, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Mon Jun 29 12:58:16 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800154, encodeId=8196800154b2, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Sun Jun 28 20:35:12 CST 2020, time=2020-06-28, status=1, ipAttribution=)]
    2020-06-29 zhaohui6731
  4. [GetPortalCommentsPageByObjectIdResponse(id=1693849, encodeId=e1371693849e3, content=<a href='/topic/show?id=3531265656b' target=_blank style='color:#2F92EE;'>#体外生命支持#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26565, encryptionId=3531265656b, topicName=体外生命支持)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=777829458008, createdName=whlxd, createdTime=Fri Apr 30 16:58:16 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078970, encodeId=a5f920e89707e, content=<a href='/topic/show?id=9911689430e' target=_blank style='color:#2F92EE;'>#生命支持#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68943, encryptionId=9911689430e, topicName=生命支持)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Mon Sep 14 00:58:16 CST 2020, time=2020-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268279, encodeId=121812682e9f6, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Mon Jun 29 12:58:16 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800154, encodeId=8196800154b2, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Sun Jun 28 20:35:12 CST 2020, time=2020-06-28, status=1, ipAttribution=)]
    2020-06-28 qingfengqishi5

    学习了,学习了

    0

相关资讯

JACC:经食道心超在结构性心脏病介入手术中的安全性研究

尽管经食道超声心动图(TEE)广泛应用于指导心脏结构性干预,但在这方面的安全性评估研究尚缺乏。本研究旨在评估心脏结构性干预中TEE操作后食管或胃损伤的发生率、并发症类型和相关因素。

JACC:左心耳封堵术和直接口服抗凝剂在高风险房颤患者中的比较研究

经皮左心耳闭合术(LAAC)在预防心房颤动(AF)相关卒中方面非劣于维生素K拮抗剂(VKAs)。然而,直接口服抗凝剂(DOACs)比VKAs具有更好的安全性,其对LAAC相关心血管和神经结局的影响尚不

JAHA:妊娠期高血压可明显增加未来心血管疾病风险

在评估妊娠合并妊娠高血压的妇女患心血管疾病风险的研究中发现了不一致的结论,本次荟萃分析旨在评估妊娠期高血压与孕妇心血管疾病风险的相关性。

JACC:导管消融可明显降低患者房颤复发率

CABANA临床研究将2204名房颤患者随机分成经导管消融治疗和药物治疗,通过意向性治疗分析显示,死亡、致残性中风、严重出血或心脏骤停的主要终点事件发生率相对减少14%,无显着性意义。本研究的目的旨在

JACC:心衰相关的临床研究发表率很低,应引起重视

临床试验结果报告不足会阻碍知识的传播,限制对治疗干预措施的理解,并可能最终伤害患者。本研究的目的旨在评估心力衰竭临床试验的发表率和预测因子,以及它们随时间的变化。

盘点:JACC六月第5期研究一览

1. 导管消融可明显降低患者房颤复发率